Search

Your search keyword '"Mu, Rong"' showing total 10 results
Start Over Author "Mu, Rong" Publication Year Range Last 50 years Journal clinical rheumatology
10 results on '"Mu, Rong"'

2. Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China

Author

Li, Chun, primary, Wang, X. R., additional, Ji, H. J., additional, Zhang, X. Y., additional, Li, X. F., additional, Wang, L. Z., additional, Wang, C. H., additional, Wang, Y. F., additional, Yang, Rong, additional, Wang, G. C., additional, Lu, Xin, additional, Zhu, Ping, additional, Chen, L. N., additional, Jin, H. T., additional, Liu, J. T., additional, Liu, X. Y., additional, Sun, Lin, additional, Chen, H. Y., additional, Wei, Ping, additional, Wang, J. X., additional, Cui, L. F., additional, Shu, Rong, additional, Liu, B. L., additional, Zhang, Z. L., additional, Li, G. T., additional, Li, Z. B., additional, Yang, Jing, additional, Li, J. F., additional, Jia, Bin, additional, Zhang, F. X., additional, Tao, J. M., additional, Han, S. L., additional, Lin, J. Y., additional, Wei, M. Q., additional, Liu, X. M., additional, Ke, Dan, additional, Hu, S. X., additional, Ye, Cong, additional, Yang, X. Y., additional, Li, Hao, additional, Huang, C. B., additional, Gao, Ming, additional, Lai, Bei, additional, Song, L. J., additional, Wang, Yi, additional, Wang, X. Y., additional, Tang, Y. D., additional, Su, Yin, additional, Mu, Rong, additional, and Li, Z. G., additional

Published
2017
Full Text
View/download PDF

3. Association of serum uric acid and risk of hypertension in adults: a prospective study of Kailuan Corporation cohort

Author

Cui, Liu-fu, primary, Shi, Hui-jing, additional, Wu, Shou-ling, additional, Shu, Rong, additional, Liu, Na, additional, Wang, Guan-ying, additional, Zhou, Bin, additional, Sun, Kai, additional, Yu, Ping, additional, Wang, Jian, additional, Song, Hai-cheng, additional, Yang, Wen-hao, additional, Wang, Jie-rui, additional, Han, Yi-xuan, additional, and Mu, Rong, additional

Published
2017
Full Text
View/download PDF

5. Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey

Author

Wang, Guan-Ying, primary, Zhang, Sa-Li, additional, Wang, Xiu-Ru, additional, Feng, Min, additional, Li, Chun, additional, An, Yuan, additional, Li, Xiao- Feng, additional, Wang, Li-Zhi, additional, Wang, Cai-Hong, additional, Wang, Yong-Fu, additional, Yang, Rong, additional, Yan, Hui-Ming, additional, Wang, Guo-Chun, additional, Lu, Xin, additional, Liu, Xia, additional, Zhu, Ping, additional, Chen, Li-Na, additional, Jin, Hong-Tao, additional, Liu, Jin-Ting, additional, Guo, Hui-Fang, additional, Chen, Hai-Ying, additional, Xie, Jian-Li, additional, Wei, Ping, additional, Wang, Jun-Xiang, additional, Liu, Xiang-Yuan, additional, Sun, Lin, additional, Cui, Liu-Fu, additional, Shu, Rong, additional, Liu, Bai-Lu, additional, Yu, Ping, additional, Zhang, Zhuo-Li, additional, Li, Guang-Tao, additional, Li, Zhen-Bin, additional, Yang, Jing, additional, Li, Jun-Fang, additional, Jia, Bin, additional, Zhang, Feng-Xiao, additional, Tao, Jie-Mei, additional, Lin, Jin-Ying, additional, Wei, Mei-Qiu, additional, Liu, Xiao-Min, additional, Ke, Dan, additional, Hu, Shao-Xian, additional, Ye, Cong, additional, Han, Shu-Ling, additional, Yang, Xiu-Yan, additional, Li, Hao, additional, Huang, Ci-Bo, additional, Gao, Ming, additional, Lai, Bei, additional, Cheng, Yong-Jing, additional, Li, Xing-Fu, additional, Song, Li-Jun, additional, Yu, Xiao-Xia, additional, Wang, Ai-Xue, additional, Wu, Li-Jun, additional, Wang, Yan-Hua, additional, He, Lan, additional, Sun, Wen-Wen, additional, Gong, Lu, additional, Wang, Xiao-Yuan, additional, Wang, Yi, additional, Zhao, Yi, additional, Li, Xiao-Xia, additional, Wang, Yan, additional, Zhang, Yan, additional, Su, Yin, additional, Zhang, Chun-Fang, additional, Mu, Rong, additional, and Li, Zhan-Guo, additional

Published
2014
Full Text
View/download PDF

6. Efficacy and safety of loxoprofen hydrogel patch versus loxoprofen tablet in patients with knee osteoarthritis: a randomized controlled non-inferiority trial

Author

Mu, Rong, primary, Bao, Chun-de, additional, Chen, Zhi-wei, additional, Zheng, Yi, additional, Wang, Guo-chun, additional, Zhao, Dong-bao, additional, Hu, Shao-xian, additional, Li, Yu-jun, additional, Shao, Zeng-wu, additional, Zhang, Zhi-yi, additional, Xiao, Wei-guo, additional, Zhang, Weiya, additional, and Li, Zhan-guo, additional

Published
2014
Full Text
View/download PDF

8. Efficacy and safety of loxoprofen hydrogel patch versus loxoprofen tablet in patients with knee osteoarthritis: a randomized controlled non-inferiority trial.

Author

Mu, Rong, Bao, Chun-de, Chen, Zhi-wei, Zheng, Yi, Wang, Guo-chun, Zhao, Dong-bao, Hu, Shao-xian, Li, Yu-jun, Shao, Zeng-wu, Zhang, Zhi-yi, Xiao, Wei-guo, Zhang, Weiya, and Li, Zhan-guo

Subjects
*NAPROXEN, *HYDROGELS, *DRUG efficacy, *MEDICATION safety, *OSTEOARTHRITIS treatment, *HEALTH outcome assessment
Abstract

This study is aimed at comparing the efficacy and safety of loxoprofen sodium hydrogel patch (LX-P) with loxoprofen sodium tablet (LX-T) in patients with knee osteoarthritis (OA). One hundred sixty-nine patients were enrolled in a randomized, controlled, double-blind, double-dummy, multicenter, non-inferiority trial of LX-P. Patients were randomly assigned to either LX-P or LX-T groups for a 4-week treatment. The primary efficacy endpoint was the proportion of patients with an overall improvement of ≥50 %, and the secondary efficacy endpoint was the proportion of patients with an improvement of ≥25 % from baseline in each of the seven main symptoms. The non-inferiority trial was based on a power of 80 % and significance level of 2.5 % with a non-inferiority margin of −10 %. In both intention-to-treat (ITT) and per-protocol (PP) analyses, LX-P was as effective as LX-T in regard to the primary endpoint. In the ITT analysis, the difference between the two groups was 12.6 % [95 % confidence interval, −1.7 to 26.9 %]. No significant differences were found between the two groups in any of the secondary efficacy outcomes. A lower incidence of adverse events was observed in LX-P group; however, the difference was not statistically significant. No serious adverse events were reported in the LX-P group, whereas one case was reported in LX-T group. Based on the present study, topical loxoprofen patch was non-inferior to oral loxoprofen in patients with knee osteoarthritis. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

9. Anti-TNF therapy in patients with HBV infection-analysis of 87 patients with inflammatory arthritis.

Author

Ye, Hua, Zhang, Xue-wu, Mu, Rong, Fang, Lin-kai, Gu, Jie-ruo, Lin, Jin, Du, Jin-feng, Chen, Jin-wei, Chen, Yi-jia, Wu, Li-jun, Pang, Xue-feng, and Li, Zhan-guo

Subjects
HEPATITIS B, VIRUS reactivation, ARTHRITIS, ETANERCEPT, INFLIXIMAB, TUMOR necrosis factors, ENZYME inhibitors, ANTIVIRAL agents
Abstract

This study aims to investigate the incidence of hepatitis B virus (HBV) reactivation in inflammatory arthritis (IA) patients with HBV infection using anti-tumor necrosis factor (TNF) agents and evaluate the efficacy of antiviral therapy in reducing the risk of viral reactivation in chronic HBV infection. IA patients using anti-TNF agents from six centers were enrolled. Their HBV infection conditions and ALT and HBV-DNA levels were monitored periodically. Among the six chronic hepatitis B patients, HBV reactivation was found in two patients without antivirus prophylaxis and no viral replication was detected in the other four patients with antivirus prophylaxis. In the 31 inactive carriers, the increase of viral load was detected in 6 of 22 (27.3 %) patients without antiviral prophylaxis, and there was no viral reactivation in the other 9 patients with antiviral prophylaxis. HBV reactivation was not found in the 50 patients with resolved HBV infection. It is suggested that anti-TNF therapy might increase the risk of HBV reactivation in patients with chronic HBV infection, and antiviral prophylaxis could effectively decrease the risk. Anti-TNF agents seem to be safe in patients with resolved HBV infection. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

10. Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey.

Author

Wang GY, Zhang SL, Wang XR, Feng M, Li C, An Y, Li XF, Wang LZ, Wang CH, Wang YF, Yang R, Yan HM, Wang GC, Lu X, Liu X, Zhu P, Chen LN, Jin HT, Liu JT, Guo HF, Chen HY, Xie JL, Wei P, Wang JX, Liu XY, Sun L, Cui LF, Shu R, Liu BL, Yu P, Zhang ZL, Li GT, Li ZB, Yang J, Li JF, Jia B, Zhang FX, Tao JM, Lin JY, Wei MQ, Liu XM, Ke D, Hu SX, Ye C, Han SL, Yang XY, Li H, Huang CB, Gao M, Lai B, Cheng YJ, Li XF, Song LJ, Yu XX, Wang AX, Wu LJ, Wang YH, He L, Sun WW, Gong L, Wang XY, Wang Y, Zhao Y, Li XX, Wang Y, Zhang Y, Su Y, Zhang CF, Mu R, and Li ZG

Subjects
Adult, Aged, Arthritis, Rheumatoid diagnosis, China, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Risk Factors, Severity of Illness Index, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Remission Induction
Abstract

The aim of this study is to investigate the remission rate of rheumatoid arthritis (RA) in China and identify its potential determinants. A multi-center cross-sectional study was conducted from July 2009 to January 2012. Data were collected by face-to-face interviews of the rheumatology outpatients in 28 tertiary hospitals in China. The remission rates were calculated in 486 RA patients according to different definitions of remission: the Disease Activity Score in 28 joints (DAS28), the Simplified Disease Activity Index (SDAI), the Clinical Disease Activity Index (CDAI), and the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definition. Potential determinants of RA remission were assessed by univariate and multivariate analyses. The remission rates of RA from this multi-center cohort were 8.6% (DAS28), 8.4% (SDAI), 8.2% (CDAI), and 6.8% (Boolean), respectively. Favorable factors associated with remission were: low Health Assessment Questionnaire (HAQ) score, absence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), and treatment of methotrexate (MTX) and hydroxychloroquine (HCQ). Younger age was also predictive for the DAS28 and the Boolean remission. Multivariate analyses revealed a low HAQ score, the absence of anti-CCP, and the treatment with HCQ as independent determinants of remission. The clinical remission rate of RA patients was low in China. A low HAQ score, the absence of anti-CCP, and HCQ were significant independent determinants for RA remission.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results